Aprea Therapeutics, Inc.
APRE
$0.90
-$0.03-3.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 285.70K | 488.20K | 841.00K | 1.28M | 1.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 285.70K | 488.20K | 841.00K | 1.28M | 1.50M |
| Cost of Revenue | 7.04M | 8.39M | 9.60M | 10.25M | 9.36M |
| Gross Profit | -6.76M | -7.91M | -8.76M | -8.96M | -7.86M |
| SG&A Expenses | 6.48M | 5.91M | 6.04M | 6.29M | 6.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.52M | 14.31M | 15.64M | 16.54M | 15.82M |
| Operating Income | -13.23M | -13.82M | -14.80M | -15.26M | -14.32M |
| Income Before Tax | -12.60M | -13.04M | -13.85M | -14.08M | -12.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.60 | -13.04 | -13.85 | -14.08 | -12.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.60M | -13.04M | -13.85M | -14.08M | -12.96M |
| EBIT | -13.23M | -13.82M | -14.80M | -15.26M | -14.32M |
| EBITDA | -13.21M | -13.80M | -14.77M | -15.23M | -14.30M |
| EPS Basic | -1.97 | -2.14 | -2.31 | -2.36 | -2.38 |
| Normalized Basic EPS | -1.23 | -1.34 | -1.44 | -1.48 | -1.49 |
| EPS Diluted | -1.97 | -2.14 | -2.31 | -2.36 | -2.38 |
| Normalized Diluted EPS | -1.23 | -1.34 | -1.44 | -1.48 | -1.49 |
| Average Basic Shares Outstanding | 26.14M | 24.40M | 23.97M | 23.83M | 22.03M |
| Average Diluted Shares Outstanding | 26.14M | 24.40M | 23.97M | 23.83M | 22.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |